{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ranibizumab+%28Lucentis+%29&page=5",
    "query": {
      "intervention": "Ranibizumab (Lucentis )",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 263,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ranibizumab+%28Lucentis+%29&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ranibizumab+%28Lucentis+%29&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T23:03:28.886Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00533520",
      "title": "Evaluation of Dosing Interval of Higher Doses of Ranibizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brandon G. Busbee, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "50 Years to 95 Years"
      },
      "enrollment_count": 37,
      "start_date": "2007-09",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2013-11-25",
      "last_synced_at": "2026-10-09T23:03:28.886Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00533520"
    },
    {
      "nct_id": "NCT01255774",
      "title": "Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The New York Eye & Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "51 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "51 Years to 90 Years"
      },
      "enrollment_count": 20,
      "start_date": "2007-06",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2011-12-05",
      "last_synced_at": "2026-10-09T23:03:28.886Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01255774"
    },
    {
      "nct_id": "NCT00464581",
      "title": "Lucentis for Treatment of Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cystoid Macular Edema"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Retina Institute of Hawaii",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "Up to 90 Years"
      },
      "enrollment_count": 30,
      "start_date": "2007-05",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2012-05-28",
      "last_synced_at": "2026-10-09T23:03:28.886Z",
      "location_count": 1,
      "location_summary": "Honolulu, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00464581"
    },
    {
      "nct_id": "NCT02471651",
      "title": "Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Dexamethasone intravitreal implant (0.7 mg)",
          "type": "DRUG"
        },
        {
          "name": "Intravitreal anti-VEGF injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "California Retina Consultants",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2015-06",
      "completion_date": "2018-10-24",
      "has_results": true,
      "last_update_posted_date": "2019-02-19",
      "last_synced_at": "2026-10-09T23:03:28.886Z",
      "location_count": 4,
      "location_summary": "Bakersfield, California • Oxnard, California • Santa Barbara, California + 1 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02471651"
    },
    {
      "nct_id": "NCT01926977",
      "title": "Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab 0.5mg",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept 2.0mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arshad Khanani",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2013-09",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2016-03-03",
      "last_synced_at": "2026-10-09T23:03:28.886Z",
      "location_count": 1,
      "location_summary": "Reno, Nevada",
      "locations": [
        {
          "city": "Reno",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01926977"
    },
    {
      "nct_id": "NCT02022540",
      "title": "Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Age-Related Macular Degeneration (AMD)"
      ],
      "interventions": [
        {
          "name": "PAN-90806 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Lucentis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PanOptica, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2014-02",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-09-28",
      "last_synced_at": "2026-10-09T23:03:28.886Z",
      "location_count": 22,
      "location_summary": "Colorado Springs, Colorado • Winter Haven, Florida • Shawnee Mission, Kansas + 19 more",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        },
        {
          "city": "Shawnee Mission",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02022540"
    },
    {
      "nct_id": "NCT03150589",
      "title": "A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "SB11 (Proposed ranibizumab biosimilar)",
          "type": "DRUG"
        },
        {
          "name": "Lucentis (ranibizumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Samsung Bioepis Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 705,
      "start_date": "2018-03-14",
      "completion_date": "2019-12-09",
      "has_results": true,
      "last_update_posted_date": "2021-05-21",
      "last_synced_at": "2026-10-09T23:03:28.886Z",
      "location_count": 19,
      "location_summary": "Poway, California • Colorado Springs, Colorado • Fort Myers, Florida + 16 more",
      "locations": [
        {
          "city": "Poway",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "‘Aiea",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03150589"
    },
    {
      "nct_id": "NCT00931489",
      "title": "Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ranibizumab (Lucentis(R))",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lawrence S. Morse, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2009-08",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-09T23:03:28.886Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00931489"
    },
    {
      "nct_id": "NCT00681889",
      "title": "Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Corneal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Reza Dana, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2008-04",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2012-11-08",
      "last_synced_at": "2026-10-09T23:03:28.886Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00681889"
    },
    {
      "nct_id": "NCT01674569",
      "title": "Pilot Study of X-82 in Patients With Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Exudative Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "X-82 oral",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab (Lucentis)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyrogenex",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2012-10",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2018-08-07",
      "last_synced_at": "2026-10-09T23:03:28.886Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • New London, Connecticut • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "New London",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Abilene",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01674569"
    }
  ]
}